Discontinue use if clinically significant decreased blood cell counts occur. Increased risk of hepatotoxicity & bone marrow suppression; aplastic anemia & agranulocytosis in patients w/ or w/o underlying hepatic dysfunction. Monitor blood count prior to & every 2 wk during treatment. Examine patients for cysticercosis retinal lesions prior to treatment of neurocysticercosis. Prolonged & high-dose use. May affect ability to drive & use machines. Pre-existing liver disease. Not to be used during pregnancy & lactation. Not to be used in childn <1 yr.
Sign Out
